
Feb 11 (Reuters) - Moleculin Biotech MBRX.O:
MOLECULIN RECEIVES FIRST COUNTRY APPROVAL IN EUROPE TO BEGIN RECRUITING FOR THE MIRACLE PHASE 3 R/R ACUTE MYELOID LEUKEMIA (AML) PIVOTAL TRIAL
MOLECULIN BIOTECH INC - FIRST SUBJECT TREATMENT IN MIRACLE TRIAL EXPECTED Q1 2025
Source text: ID:nPn7y6kN7a
Further company coverage: MBRX.O